Results 251 to 260 of about 53,302 (297)

Molecular Weight of Type A Botulinum Toxin

Infection and Immunity, 1970
Clostridium botulinum type A does not produce a 12,000 molecular weight toxin. The reported isolation of such a material by Gerwing et al. could not be confirmed.
J N, Knox, W P, Brown, L, Spero
openaire   +2 more sources

Botulinum Toxin Type A for Chronic Migraine

Current Neurology and Neuroscience Reports, 2010
Chronic migraine (CM) is the leading cause of chronic daily headache, a common and debilitating headache syndrome. The management of CM patients is challenging, with only limited benefit from available oral preventive medications. Botulinum neurotoxin (BoNT) has been used extensively to treat disorders associated with increased muscle tone. More recent
openaire   +2 more sources

Botulinum Toxin Type B (Myobloc)

Dermatologic Surgery, 2003
Myobloc, known as Neurobloc in Europe, is a member of the botulinum toxin family. It has been used for a myriad of problems since its approval in the United States in December 2000. It is currently not approved for cosmetic use but has been used for this purpose. This article reviews what is currently known about botulinum toxin type B and its efficacy
Leslie, Baumann, Laura, Black
openaire   +2 more sources

Pharmacology and immunology of botulinum toxin type A

Clinics in Dermatology, 2003
The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody ...
openaire   +2 more sources

Observations on the Type A Toxin of Clostridium botulinum

Nature, 1951
THE recent communication by Wentzel, Sterne and Polson1 makes it desirable to record some supplementary observations made in the chemical investigation of a number of toxins, especially that produced by Clostridium botulinum Type A. In the present experiments, the toxicity was determined by intraperitoneal injection into white mice of 20 gm. weight.
openaire   +2 more sources

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Movement Disorders, 2002
AbstractIn some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop.
Dirk, Dressler, Hans, Bigalke
openaire   +2 more sources

Botulinum toxin type A for the treatment of migraine

Expert Opinion on Pharmacotherapy, 2006
Migraine is a common and debilitating disorder that often requires prophylactic therapy, particularly for those migraine patients who meet the diagnostic criteria for chronic daily headache (chronic migraine). Existing prophylactic treatments for migraine are inadequate for many patients due to their modest efficacy and/or systemic side effects ...
openaire   +2 more sources

Botulinum toxin type A

Journal of the American Academy of Dermatology, 2005
Alastair, Carruthers, Jean, Carruthers
openaire   +2 more sources

Botulinum toxin type a for blepharospasm

Parkinsonism & Related Disorders, 2023
A. Duarte, H.A. Ghizoni Teive
semanticscholar   +1 more source

Botulinum Toxin Type A

Dermatologic Surgery, 2007
GEORGE KONTOCHRISTOPOULOS, ATHINA N. KATSAVOU, OLGA KALOGIROU, STELIOS AGELIDIS, NIKOLETA ZAKOPOULOU   +4 more
openaire   +1 more source